Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pioglitazone + metformin + liraglutide
- Development stage
- Unknown
- Lead developer
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Modality
- Peptides, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
Pioglitazone + metformin + liraglutide is a triple combination therapy investigated for the treatment of type 2 diabetes mellitus and metabolic-associated fatty liver disease (MAFLD). This therapeutic regimen combines three distinct pharmacological agents: pioglitazone, a thiazolidinedione that activates the peroxisome proliferator-activated receptor gamma (PPAR-gamma) to enhance insulin sensitivity; metformin, a biguanide that primarily reduces hepatic glucose production through the activation of AMP-activated protein kinase (AMPK); and liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that stimulates glucose-dependent insulin secretion and promotes weight loss. Developed and studied by Shandong Provincial Hospital, this combination aims to provide a comprehensive approach to metabolic dysfunction by addressing insulin resistance, hyperglycemia, and hepatic steatosis simultaneously.
- Other names
- Triple therapy of pioglitazone, metformin, and liraglutide
02
Targets
ND1 (Mitochondrial electron transport chain complex I)AMPK (Adenosine monophosphate–activated protein kinase)PPARG (Peroxisome proliferator-activated receptor gamma)GLP1R (GLP-1R)
Beyond the preview
Go deeper on pioglitazone + metformin + liraglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pioglitazone + metformin + liraglutide.